SeedFolio

TRIO Pharmaceuticals is a cancer therapeutics company focused on developing innovative treatments that enhance efficacy, minimize toxicity, and improve affordability of cancer drugs. The company is comprised of an experienced team in cancer drug discovery and development, with a history of creating approved cancer therapies. Unlike conventional treatments that rely on single-agent approaches to either inhibit cancer cell growth or reduce immunosuppression, TRIO Pharmaceuticals is pioneering single-agent multi-action therapies. These therapies aim to inhibit both cancer growth and immunosuppression, addressing the limitations of existing treatments, particularly for patients who have not responded to immune checkpoint therapies. The company's approach specifically targets antigens on cancer cells and immunosuppressor cells, aiming to generate immunogenic tumors and meet the high unmet medical needs in oncology.

VerImmune, based in Baltimore, Maryland, is an immuno-oncology company focused on developing innovative cancer therapies through a unique approach called Anti-tumor Immune Redirection. The company employs proprietary virus-inspired particles, known as Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs), which harness pre-existing immune memory from past infections or childhood vaccinations to target tumors. This strategy aims to offer a new treatment option for patients with limited alternatives or those who have developed resistance to conventional cancer therapies. VerImmune's technology seeks to deliver low toxicity and sustainable benefits across a wide array of cancers, potentially reshaping the treatment landscape for difficult-to-treat cases.

Veckta is an energy transition market platform that focuses on the development of distributed energy systems (DES) and microgrid projects. It combines advanced energy system engineering tools with a comprehensive marketplace, enabling businesses and communities to assess their current energy needs and customize solutions tailored to their specific requirements related to cost, reliability, and emissions. The platform facilitates seamless engagement with vetted capital, construction, and equipment suppliers, allowing clients to design, finance, and build their energy systems effectively. By providing transparent and competitive pricing along with global support, Veckta empowers users to make informed decisions, fostering sustainable and profitable energy solutions for various stakeholders.

eGlint is a developer of a miniature biosensing device that utilizes a small volume of blood to detect multiple biomarkers. This innovative technology aims to enhance the efficiency of biomarker identification in the medical field. By offering a device capable of analyzing various biomarkers from a minimal blood sample, eGlint seeks to improve diagnostic processes and patient care within the healthcare industry.

Amplo Biotechnology is focused on developing innovative Adeno-Associated Viral (AAV) therapies aimed at addressing severe diseases related to the neuromuscular junction, which can lead to paralysis, breathing difficulties, and swallowing challenges. The company targets conditions such as congenital myasthenic syndromes, leveraging its lead program, AAV-Dok7, developed by a research group at the University of Tokyo. The therapies are administered through intravascular injections, initiating molecular processes that enable effective treatment for patients suffering from these rare disorders. Amplo’s mission is to create potentially curative solutions for conditions that significantly impact patient health and quality of life.

Deep Blue Medical Advances, Inc. manufactures hernia mesh for hernia patients. The company offers T-Line® hernia mesh and anchor clips to patients. Deep Blue Medical Advances, Inc. was incorporated in 2015 and is based in Durham, North Carolina with an additional office in San Francisco, California.

Allotrope Medical Inc. is a Houston-based medical device company focused on enhancing surgical procedures by developing innovative devices for ureter identification. The company's flagship product, the StimSite, is an intuitive handheld device that aids surgeons in quickly and accurately locating ureters during pelvic surgeries. This device features a simple design with a single button, eliminating the need for complex pre- and post-operative procedures. Founded in 2016, Allotrope Medical aims to improve surgical outcomes by providing tools that streamline the identification and localization of ureters, thus facilitating safer and more efficient operations.